CD133 ligand-enhanced etoposide-liposome complex for targeted killing of lung cancer cells
Lung cancer has a high incidence rate and a low cure rate, hence the urgent need for effective treatment methods. Current lung cancer drugs have several drawbacks, including low specificity, poor targeting, drug resistance, and irreversible damage to normal tissues. Therefore, there is a need to dev...
Gespeichert in:
| Veröffentlicht in: | Biotechnology progress 2024-09, Vol.40 (5), p.e3460 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | e3460 |
| container_title | Biotechnology progress |
| container_volume | 40 |
| creator | Nie, Shiwei Zhou, Junzheng Zheng, Xiaodong Wei, Xudong Zhang, Jinrui Shen, Xiaojuan Zhang, Weimin |
| description | Lung cancer has a high incidence rate and a low cure rate, hence the urgent need for effective treatment methods. Current lung cancer drugs have several drawbacks, including low specificity, poor targeting, drug resistance, and irreversible damage to normal tissues. Therefore, there is a need to develop a safe and effective new drug that can target and kill tumor cells. In this study, we combined nanotechnology and biotechnology to develop a CD133 ligand-modified etoposide-liposome complex (Lipo@ETP-CD133) for targeted therapy of lung cancer. The CD133 ligand targeted lung cancer stem cells, causing the composite material to aggregate at the tumor site, where high levels of ETP liposomes could exert a strong tumor-killing effect. Our research results demonstrated that this nano-drug had efficient targeting and tumor-killing effects, indicating its potential for clinical application. |
| doi_str_mv | 10.1002/btpr.3460 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3031133138</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3116301401</sourcerecordid><originalsourceid>FETCH-LOGICAL-c273t-37e780aa100e11e9cbf29fd9a34c06bf655ca6a522fc92b898ac3961f205f1403</originalsourceid><addsrcrecordid>eNpdkDtPxDAQhC0EguNR8AdQJBooAmvv2XFKdDwlJBpoaCLHsY-AEwc7keDf44hHQTVbfDuaGUIOKZxRAHZej0M4w6WADbKgnEEuAHGTLGTBRV6UKHfIboyvACBBsG2yg5JzyZd8QZ5XlxQxc-1a9U1u-hfVa9NkZvSDj21jctemw3cm074bnPnIrA_ZqMLajIl7a51r-3XmbeampHp-D5k2zsV9smWVi-bgR_fI0_XV4-o2v3-4uVtd3OeaFTjmWJhCglKpiaHUlLq2rLRNqXCpQdRWcK6VUJwxq0tWy1IqjaWglgG3dAm4R06-fYfg3ycTx6pr45xA9cZPsUJAmjpSlAk9_oe--in0KV2VGIGQ_GiiTr8pHXyMwdhqCG2nwmdFoZoHr-bBq3nwxB79OE51Z5o_8ndh_AI1znqq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3116301401</pqid></control><display><type>article</type><title>CD133 ligand-enhanced etoposide-liposome complex for targeted killing of lung cancer cells</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Nie, Shiwei ; Zhou, Junzheng ; Zheng, Xiaodong ; Wei, Xudong ; Zhang, Jinrui ; Shen, Xiaojuan ; Zhang, Weimin</creator><creatorcontrib>Nie, Shiwei ; Zhou, Junzheng ; Zheng, Xiaodong ; Wei, Xudong ; Zhang, Jinrui ; Shen, Xiaojuan ; Zhang, Weimin</creatorcontrib><description>Lung cancer has a high incidence rate and a low cure rate, hence the urgent need for effective treatment methods. Current lung cancer drugs have several drawbacks, including low specificity, poor targeting, drug resistance, and irreversible damage to normal tissues. Therefore, there is a need to develop a safe and effective new drug that can target and kill tumor cells. In this study, we combined nanotechnology and biotechnology to develop a CD133 ligand-modified etoposide-liposome complex (Lipo@ETP-CD133) for targeted therapy of lung cancer. The CD133 ligand targeted lung cancer stem cells, causing the composite material to aggregate at the tumor site, where high levels of ETP liposomes could exert a strong tumor-killing effect. Our research results demonstrated that this nano-drug had efficient targeting and tumor-killing effects, indicating its potential for clinical application.</description><identifier>ISSN: 8756-7938</identifier><identifier>ISSN: 1520-6033</identifier><identifier>EISSN: 1520-6033</identifier><identifier>DOI: 10.1002/btpr.3460</identifier><identifier>PMID: 38558545</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>AC133 Antigen - metabolism ; Animals ; Biotechnology ; Cell Line, Tumor ; Composite materials ; Drug delivery ; Drug Delivery Systems ; Drug resistance ; Etoposide ; Etoposide - chemistry ; Etoposide - pharmacology ; Humans ; Ligands ; Liposomes ; Liposomes - chemistry ; Lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - metabolism ; Lung Neoplasms - pathology ; Mice ; Nanotechnology ; Neoplastic Stem Cells - drug effects ; Stem cells ; Tumor cells ; Tumors</subject><ispartof>Biotechnology progress, 2024-09, Vol.40 (5), p.e3460</ispartof><rights>2024 American Institute of Chemical Engineers.</rights><rights>2024 American Institute of Chemical Engineers</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c273t-37e780aa100e11e9cbf29fd9a34c06bf655ca6a522fc92b898ac3961f205f1403</cites><orcidid>0009-0008-3689-4516</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38558545$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nie, Shiwei</creatorcontrib><creatorcontrib>Zhou, Junzheng</creatorcontrib><creatorcontrib>Zheng, Xiaodong</creatorcontrib><creatorcontrib>Wei, Xudong</creatorcontrib><creatorcontrib>Zhang, Jinrui</creatorcontrib><creatorcontrib>Shen, Xiaojuan</creatorcontrib><creatorcontrib>Zhang, Weimin</creatorcontrib><title>CD133 ligand-enhanced etoposide-liposome complex for targeted killing of lung cancer cells</title><title>Biotechnology progress</title><addtitle>Biotechnol Prog</addtitle><description>Lung cancer has a high incidence rate and a low cure rate, hence the urgent need for effective treatment methods. Current lung cancer drugs have several drawbacks, including low specificity, poor targeting, drug resistance, and irreversible damage to normal tissues. Therefore, there is a need to develop a safe and effective new drug that can target and kill tumor cells. In this study, we combined nanotechnology and biotechnology to develop a CD133 ligand-modified etoposide-liposome complex (Lipo@ETP-CD133) for targeted therapy of lung cancer. The CD133 ligand targeted lung cancer stem cells, causing the composite material to aggregate at the tumor site, where high levels of ETP liposomes could exert a strong tumor-killing effect. Our research results demonstrated that this nano-drug had efficient targeting and tumor-killing effects, indicating its potential for clinical application.</description><subject>AC133 Antigen - metabolism</subject><subject>Animals</subject><subject>Biotechnology</subject><subject>Cell Line, Tumor</subject><subject>Composite materials</subject><subject>Drug delivery</subject><subject>Drug Delivery Systems</subject><subject>Drug resistance</subject><subject>Etoposide</subject><subject>Etoposide - chemistry</subject><subject>Etoposide - pharmacology</subject><subject>Humans</subject><subject>Ligands</subject><subject>Liposomes</subject><subject>Liposomes - chemistry</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - metabolism</subject><subject>Lung Neoplasms - pathology</subject><subject>Mice</subject><subject>Nanotechnology</subject><subject>Neoplastic Stem Cells - drug effects</subject><subject>Stem cells</subject><subject>Tumor cells</subject><subject>Tumors</subject><issn>8756-7938</issn><issn>1520-6033</issn><issn>1520-6033</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkDtPxDAQhC0EguNR8AdQJBooAmvv2XFKdDwlJBpoaCLHsY-AEwc7keDf44hHQTVbfDuaGUIOKZxRAHZej0M4w6WADbKgnEEuAHGTLGTBRV6UKHfIboyvACBBsG2yg5JzyZd8QZ5XlxQxc-1a9U1u-hfVa9NkZvSDj21jctemw3cm074bnPnIrA_ZqMLajIl7a51r-3XmbeampHp-D5k2zsV9smWVi-bgR_fI0_XV4-o2v3-4uVtd3OeaFTjmWJhCglKpiaHUlLq2rLRNqXCpQdRWcK6VUJwxq0tWy1IqjaWglgG3dAm4R06-fYfg3ycTx6pr45xA9cZPsUJAmjpSlAk9_oe--in0KV2VGIGQ_GiiTr8pHXyMwdhqCG2nwmdFoZoHr-bBq3nwxB79OE51Z5o_8ndh_AI1znqq</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Nie, Shiwei</creator><creator>Zhou, Junzheng</creator><creator>Zheng, Xiaodong</creator><creator>Wei, Xudong</creator><creator>Zhang, Jinrui</creator><creator>Shen, Xiaojuan</creator><creator>Zhang, Weimin</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0008-3689-4516</orcidid></search><sort><creationdate>20240901</creationdate><title>CD133 ligand-enhanced etoposide-liposome complex for targeted killing of lung cancer cells</title><author>Nie, Shiwei ; Zhou, Junzheng ; Zheng, Xiaodong ; Wei, Xudong ; Zhang, Jinrui ; Shen, Xiaojuan ; Zhang, Weimin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c273t-37e780aa100e11e9cbf29fd9a34c06bf655ca6a522fc92b898ac3961f205f1403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>AC133 Antigen - metabolism</topic><topic>Animals</topic><topic>Biotechnology</topic><topic>Cell Line, Tumor</topic><topic>Composite materials</topic><topic>Drug delivery</topic><topic>Drug Delivery Systems</topic><topic>Drug resistance</topic><topic>Etoposide</topic><topic>Etoposide - chemistry</topic><topic>Etoposide - pharmacology</topic><topic>Humans</topic><topic>Ligands</topic><topic>Liposomes</topic><topic>Liposomes - chemistry</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - metabolism</topic><topic>Lung Neoplasms - pathology</topic><topic>Mice</topic><topic>Nanotechnology</topic><topic>Neoplastic Stem Cells - drug effects</topic><topic>Stem cells</topic><topic>Tumor cells</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nie, Shiwei</creatorcontrib><creatorcontrib>Zhou, Junzheng</creatorcontrib><creatorcontrib>Zheng, Xiaodong</creatorcontrib><creatorcontrib>Wei, Xudong</creatorcontrib><creatorcontrib>Zhang, Jinrui</creatorcontrib><creatorcontrib>Shen, Xiaojuan</creatorcontrib><creatorcontrib>Zhang, Weimin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biotechnology progress</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nie, Shiwei</au><au>Zhou, Junzheng</au><au>Zheng, Xiaodong</au><au>Wei, Xudong</au><au>Zhang, Jinrui</au><au>Shen, Xiaojuan</au><au>Zhang, Weimin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CD133 ligand-enhanced etoposide-liposome complex for targeted killing of lung cancer cells</atitle><jtitle>Biotechnology progress</jtitle><addtitle>Biotechnol Prog</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>40</volume><issue>5</issue><spage>e3460</spage><pages>e3460-</pages><issn>8756-7938</issn><issn>1520-6033</issn><eissn>1520-6033</eissn><abstract>Lung cancer has a high incidence rate and a low cure rate, hence the urgent need for effective treatment methods. Current lung cancer drugs have several drawbacks, including low specificity, poor targeting, drug resistance, and irreversible damage to normal tissues. Therefore, there is a need to develop a safe and effective new drug that can target and kill tumor cells. In this study, we combined nanotechnology and biotechnology to develop a CD133 ligand-modified etoposide-liposome complex (Lipo@ETP-CD133) for targeted therapy of lung cancer. The CD133 ligand targeted lung cancer stem cells, causing the composite material to aggregate at the tumor site, where high levels of ETP liposomes could exert a strong tumor-killing effect. Our research results demonstrated that this nano-drug had efficient targeting and tumor-killing effects, indicating its potential for clinical application.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38558545</pmid><doi>10.1002/btpr.3460</doi><orcidid>https://orcid.org/0009-0008-3689-4516</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 8756-7938 |
| ispartof | Biotechnology progress, 2024-09, Vol.40 (5), p.e3460 |
| issn | 8756-7938 1520-6033 1520-6033 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3031133138 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE |
| subjects | AC133 Antigen - metabolism Animals Biotechnology Cell Line, Tumor Composite materials Drug delivery Drug Delivery Systems Drug resistance Etoposide Etoposide - chemistry Etoposide - pharmacology Humans Ligands Liposomes Liposomes - chemistry Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Lung Neoplasms - pathology Mice Nanotechnology Neoplastic Stem Cells - drug effects Stem cells Tumor cells Tumors |
| title | CD133 ligand-enhanced etoposide-liposome complex for targeted killing of lung cancer cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T08%3A14%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CD133%20ligand-enhanced%20etoposide-liposome%20complex%20for%20targeted%20killing%20of%20lung%20cancer%20cells&rft.jtitle=Biotechnology%20progress&rft.au=Nie,%20Shiwei&rft.date=2024-09-01&rft.volume=40&rft.issue=5&rft.spage=e3460&rft.pages=e3460-&rft.issn=8756-7938&rft.eissn=1520-6033&rft_id=info:doi/10.1002/btpr.3460&rft_dat=%3Cproquest_cross%3E3116301401%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3116301401&rft_id=info:pmid/38558545&rfr_iscdi=true |